Melbourne (Australia) | 27 October 2022
Telix is today pleased to announce that it has been awarded Australian Company of the Year in the 2022 AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards, held today at the AusBiotech 2022 national conference in Perth.
The awards recognise innovative companies and individuals in Australia’s world-class biotechnology, medical technology and healthcare sectors. The Company of the Year Award is judged by an industry-leading panel and awarded to an Australian company that has demonstrated significant achievement in the areas of biotechnology or life sciences.
Dr Christian Behrenbruch, Group CEO and Managing Director of Telix, said, “We are honoured to be recognised by AusBiotech, Johnson & Johnson Innovation and our industry peers on the judging panel as the 2022 Company of the Year. It comes in a pivotal year, which has seen Telix successfully launch its first commercial product Illuccix® for prostate cancer imaging, while continuing to develop a significant pipeline of products that address unmet medical need. This recognition serves to inspire our team to continue to drive change and pursue our purpose to help people with cancer and rare diseases live longer, better quality lives. We are very proud to be a part of Australia’s thriving, world-class life sciences sector and we thank AusBiotech for the important role it plays in supporting our industry.”
To read the full media release, click here
About Telix Pharmaceuticals Limited
Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals. Telix is headquartered in Melbourne, Australia with international operations in the United States, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical-stage products that aims to address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com and follow Telix on Twitter(@TelixPharma) and LinkedIn.
Telix's lead product, Illuccix (kit for preparation of Ga-68 Glu-urea-Lys(ahx)-hbed-CC Injection), also known as 68Ga-PSMA-11 injection, has been approved by the U.S. Food and Drug Administration (FDA), and by the Australian Therapeutic Goods Administration (TGA), and by Health Canada.
AusBiotech is Australia's biotechnology organisation, working on behalf of members for more than 35 years to provide representation and services to promote the global growth of Australian biotechnology. AusBiotech is a well-connected network of over 3,000 members in the life sciences, including therapeutics, medical technology (devices and diagnostics), food technology and agricultural sectors.